This Project Grant award from the National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK) under the Diabetes, Digestive, and Kidney Diseases Extramural Research program (CFDA 93.847) is for the development and testing of a device to predict the risk of severe acute kidney injury (AKI). The $548,830 award to Nephsmart LLC, a for-profit limited liability company, will fund the creation of a point-of-care test that can detect cleavage of a specific protein in urine, which preliminary data suggest is highly predictive of the future development of severe AKI. The award period runs from August 1, 2024 to July 31, 2025. If successful, this device has the potential to significantly improve clinical management of AKI, which is a major cause of morbidity and mortality.
Generated 3/4/25, 7:22 AM